Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot multiple sclerosis (MS) imaging study conducted with Massachusetts General Hospital. Preliminary PET imaging data from the study have shown encouraging signals in acute MS lesions, suggesting that the novel imaging technique may be able to distinguish between demyelinated nerve fibers that could still be viable and those that have suffered permanent damage. This capability could provide a more precise method for measuring myelin loss and repair, which is critical for assessing disease progression and treatment efficacy.
The relevance of these findings extends to Lucid-MS, Quantum BioPharma's investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation. As noted in a recent article, “These findings are directly relevant to Lucid-MS... A more precise imaging tool and a drug candidate designed to address the underlying cause of MS make for a compelling combination. Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions.”
The full article can be accessed at https://nnw.fm/fsDHa.
Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Its lead compound, Lucid-MS, is a patented new chemical entity that has shown in preclinical models the ability to prevent and reverse myelin degradation, the underlying mechanism of MS. The company also invented unbuzzd, an over-the-counter product, and spun out its OTC version to Unbuzzd Wellness Inc. (UWI), led by industry veterans. Quantum BioPharma retains a 19.84% ownership stake in UWI (as of March 31, 2026) and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Additionally, Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The progress of the imaging study is a significant milestone for Quantum BioPharma, as it validates the potential of its imaging technique to provide more accurate assessments of myelin damage and repair. This could ultimately support the clinical development of Lucid-MS, offering new hope for patients with MS. The preliminary results suggest that the science is robust, and the company is moving forward with patient enrollment.
For more information about Quantum BioPharma and its latest updates, visit the company's newsroom at https://ibn.fm/QNTM. The original press release is available at https://www.newmediawire.com.
